Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Dendreon Corporation (NasdaqNM:DNDN)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials
Location
3005 First Avenue
Seattle, WA 98121
Phone: (206) 256-4545
Fax: (206) 256-0571
Email: pr@dendreon.com
Employees (last reported count): 99
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 69%
·Over the last 6 months:
 · 3 insider sells; 31.0K shares
  (0.2% of insider shares)
·Institutional: 30% (97% of float)
(66 institutions)
·Net Inst. Buying: 942.0K shares (+11.23%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Dendreon Corporation discovers and develops immunologically based therapeutic products for the treatment of cancer. The Company's lead product, Provenge, is a therapeutic vaccine for the treatment of prostate cancer and is in Phase III clinical trials, the final stage of product development. Dendreon is conducting Phase II clinical trials for Mylovenge, its therapeutic vaccine for the treatment of multiple myeloma. The Company's vaccine for the treatment of breast, ovarian and colon cancer, APC8024, was cleared by the Food and Drug Administration to begin Phase I clinical trials at the end of 2000. The Company has additional therapeutic vaccines in preclinical development for the treatment of common malignancies, including lung, bladder and uterine cancers.
More from Market Guide: Expanded Business Description

Financial Summary
Dendreon Corp. is engaged in the research and development of immunologically-based therapeutic products for the treatment of cancer. The Company develops vaccines that stimulate cancer-fighting cells. For the six months ended 6/30/01, total revenues rose from $2.3 million to $6.2 million. Net loss applicable to Common fell 31% to $8.3 million. Revenues reflect agreements with R.W. Johnson. Lower loss reflects higher interest income due to higher average cash balances.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Christopher Henney, Ph.D., 60
Chairman, CEO
$615K$2.0M
David Urdal, Ph.D., 51
Vice Chairman, Pres and CSO
450K663K
Martin Simonetti, 43
CFO, Sr. VP-Fin., Treasurer
290K225K
T. Dennis George, 62
Sr. VP- Corp. Affairs, Gen. Counsel, Sec.
245K--  
Frank Valone, M.D., 51
Sr. VP, Medical and Regulatory Affairs and CMO
330K90K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:DNDNAs of 31-Aug-2001
Price and Volume
52-Week Low
on 5-Apr-2001
$5.625
Recent Price$9.65 
52-Week High
on 27-Sep-2000
$26.625
Daily Volume (3-month avg)83.1K
Daily Volume (10-day avg)48.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y]
52-Week Change-49.2%
52-Week Change
relative to S&P500
-31.9%
Share-Related Items
Market Capitalization$239.6M
Shares Outstanding24.8M
Float7.70M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$3.19 
Earnings (ttm)-$0.70 
Earnings (mrq)-$0.21 
Sales (ttm)$0.44 
Cash (mrq)$3.01 
Valuation Ratios
Price/Book (mrq)3.03 
Price/EarningsN/A 
Price/Sales (ttm)21.91 
Income Statements
Sales (ttm)$10.4M
EBITDA (ttm)-$20.1M
Income available to common (ttm)-$16.5M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-19.03%
Return on Equity (ttm)-23.88%
Financial Strength
Current Ratio (mrq)5.75 
Debt/Equity (mrq)0.04 
Total Cash (mrq)$74.5M
Short Interest
As of 8-Aug-2001
Shares Short203.0K
Percent of Float2.6%
Shares Short
(Prior Month)
323.0K
Short Ratio3.27 
Daily Volume62.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.